Clinical Trials Logo

Clinical Trial Summary

Background: - Atopic dermatitis, or eczema, is a chronic skin disorder. Patients sometimes have infections with S. aureus bacteria. Researchers want to study how eczema treatments affect the number and the type of bacteria on the skin. Objectives: - To study the effect of eczema treatments on skin bacteria. Eligibility: - Individuals between 2 and 25 years of age who have moderate to severe atopic dermatitis. - Healthy volunteers between 18 and 40 years of age with no history of eczema. Design: - Participants will be screened with a physical exam and medical history. Research samples will be collected. Skin biopsies may also be performed. - All participants will be assigned to one of several study groups. - This study will last for up to 1 year. Healthy volunteers must not have taken antibiotics in the year before the start of the study. - All participants will have regular study visits during their 1-year participation. More research samples will be collected at these visits.


Clinical Trial Description

BACKGROUND: - The use of antibiotics has revolutionized medicine, yet the impact of antimicrobials on the human microbiome is incompletely understood. - Antimicrobial treatments, including topical and systemic antibiotics, are highly effective and are frequently used to manage disease flares of AD. Concomitant use of dilute bleach baths reduces the clinical severity of AD in patients with clinical signs of bacterial skin infections. - The longitudinal impact of various antimicrobials on the human microbiome, particularly in skin, has not been systematically investigated. OBJECTIVES: Primary: -To characterize microbiome alterations in healthy adult volunteers (Cohorts 1 and 2) and patients with AD (Cohort 3) after antimicrobial treatments. ELIGIBILITY: - All subjects must be co-enrolled in NIH protocol 08-HG-0059 - (Cohorts 1 and 2) Healthy volunteers aged 18 to 50 years with no history of AD - (Cohort 1 and 2) No prior use of systemic antibiotics in preceding 12 months - (Cohort 3) Subjects 2-50 years with atopic dermatitis with symptoms of active bacterial infection - (Cohort 3) Objective SCORAD (SCORing Atopic Dermatitis) score of greater than or equal to 15 indicating moderate-to-severe disease DESIGN: - A prospective, interventional, longitudinal study examining changes in microbiome resulting from randomized, placebo-controlled, investigator-blinded antimicrobial treatments. - Subjects in Cohort 1 will be randomized to take one of 4 open label antibiotic regimens. - Subjects from Cohort 2 will be will be randomized to one of four possible blinded treatment combinations of study baths and antibiotics. - Subjects in Cohort 3 will be randomized to a cephalexin regimen with or without study baths. - All subjects will undergo longitudinal microbiome sampling. - AD patients will undergo clinical assessment to determine responses of skin infections to treatment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01631617
Study type Interventional
Source National Institutes of Health Clinical Center (CC)
Contact Monica Taylor, R.N.
Phone (301) 451-2221
Email monica.taylor@nih.gov
Status Recruiting
Phase Phase 2
Start date September 18, 2012
Completion date January 1, 2025

See also
  Status Clinical Trial Phase
Completed NCT03563066 - Effect of Benralizumab in Atopic Dermatitis Phase 2
Terminated NCT04086121 - A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032 Phase 2
Recruiting NCT04011215 - Wool Clothing for the Management of Childhood Atopic Dermatitis (DESSINE2) N/A
Completed NCT04635072 - Stabilized Whole Rice Bran (SWRB) for Mild to Moderate Atopic Dermatitis Early Phase 1
Completed NCT02916888 - A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists N/A
Completed NCT01945086 - A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic Dermatitis Phase 2
Completed NCT00541255 - A Long-Term Examination of Asthma From Childhood Through Adolescence
Terminated NCT04990440 - A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis Phase 2
Completed NCT02900131 - Efficacy, Safety and Dose Finding Trial of Topical Jaungo Application in Atopic Dermatitis Patients Phase 2
Completed NCT03568136 - Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis Phase 2
Completed NCT03672383 - Functional Study to Investigate the Efficacy of a New Medical Device (Modified Diprobase Formulation) N/A
Completed NCT03634345 - Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842. Phase 1
Enrolling by invitation NCT04761978 - Efficacy and Tolerance of JAK Inhibitors in ATU for Atopic Dermatitis
Completed NCT03663673 - Effect of Different Skin Creams on TEWL Phase 1
Recruiting NCT05177744 - Toxicity of Micro and Nano Plastics Combined With Environmental Contaminants on the Risk of Allergic Disease
Completed NCT03720470 - Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy Phase 3
Completed NCT02637206 - Skin Irritation Study of GSK2894512 Cream Phase 1
Completed NCT05544591 - Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis Phase 2
Completed NCT05094700 - A Study of a Polymeric Surfactant Technology Cleanser in Sensitive Skin Participants N/A
Terminated NCT02582788 - Bathing Additives in Pediatric Atopic Dermatitis N/A